Shots:

• Stoke to receive a $60M upfront, ~$907M in milestones along with royalties while both companies will share 50/50 costs globally & profits for the SYNGAP1 program. Acadia gets exclusive licenses for 2 preclinical programs i.e., Rett syndrome (MECP2) & undisclosed neurodevelopmental target
• The collaboration will combine Stoke’s TANGO research platform with Acadia’s expertise to develop RNA-based therapies for rare CNS disorders
• Stoke will lead the research & pre-clinical development activities for Rett syndrome & the undisclosed neurodevelopmental program. Acadia will lead clinical development & commercialization activities & fund the research & pre-clinical activities for 2 targets

Ref: Acadia | Image: Businesswire